Gilead Sciences (GILD) Tops Q3 EPS by 94c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Gilead Sciences (GILD) Tops Q3 EPS by 94c
October 29, 2021 7:31 AM EDT
Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, which is designed to evaluate the antiviral effectiveness and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in 1,135 people living with HIV. The BICSTaR study also collected patient-reported outcomes in routine clinical practice to better understand the impact of treatment on health-related quality... More
October 26, 2021 6:47 AM EDT
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the start of a Phase 2 clinical study evaluating an investigational once-weekly oral combination treatment regimen of islatravir and lenacapavir in people living with HIV who are virologically suppressed on antiretroviral therapy.
Partnerships and collaborations are critical to continuing the tremendous progress that has been made toward ending the HIV epidemic, said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. This innovative research... More
